Buerger's Disease Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Global Leaders - DelveInsight | Featuring Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences

With Buerger's Disease reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Buerger's Disease pipeline comprises 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting Buerger's Disease. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Buerger's Disease Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Buerger's Disease Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Buerger's Disease Drug Development @ https://www.delveinsight.com/report-store/buergers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Buerger's Disease Pipeline Report

DelveInsight's Buerger's Disease pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Buerger's Disease treatment.
Key Buerger's Disease companies such as Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences, and others are evaluating new drugs for Buerger's Disease to improve the treatment landscape.
Promising Buerger's Disease pipeline therapies in various stages of development include Mesenchymal stem cell therapy, ATI-1013, and others.

Buerger's Disease Overview:

Buerger's disease, medically termed Thromboangiitis obliterans, is a rare condition that causes inflammation and blockage of small and medium-sized blood vessels, primarily in the hands and feet. Early symptoms often include pain or a sensation of coldness in the fingers or toes, while more advanced stages can lead to discoloration (pale, red, or bluish skin), intense pain, skin ulcers, gangrene, and in severe cases, amputation.

Diagnosis involves imaging tests to detect blood vessel blockages, such as plethysmography, Doppler ultrasound, or catheter-based X-ray arteriography. Additional blood tests may be conducted to rule out other forms of vasculitis or vascular occlusion.

The main treatment goal is to relieve symptoms and halt disease progression. The only proven method to significantly improve outcomes and lower the risk of amputation is complete cessation of all tobacco products, including smoking, exposure to secondhand smoke, and nicotine replacement therapies, especially if done before irreversible tissue damage occurs. Additional medical options include calcium channel blockers, blood thinners (anticoagulants), clot-dissolving agents (thrombolytics), prostaglandin analogs, and in some cases, procedures like sympathectomy, adrenalectomy, spinal cord stimulation, or omental transfer.

Download the Buerger's Disease sample report to know in detail about the Buerger's Disease treatment market @ https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Buerger's Disease Pipeline Analysis
The Buerger's Disease pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Buerger's Disease Market.

Categorizes Buerger's Disease therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Buerger's Disease drugs under development based on:

Stage of development

Buerger's Disease Route of administration

Target receptor

Monotherapy vs. combination therapy

Buerger's Disease Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Buerger's Disease Licensing agreements

Funding and investment activities supporting future Buerger's Disease market advancement.

Unlock key insights into emerging Buerger's Disease therapies and market strategies here: https://www.delveinsight.com/report-store/buergers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Buerger's Disease Emerging Drugs

Mesenchymal Stem Cell Therapy - K-STEMCELL
K-STEMCELL is developing a mesenchymal stem cell-based treatment aimed at healing ischemic ulcers and related complications caused by Buerger's disease. The investigational therapy, VascoStem, promotes indirect blood vessel formation through the secretion of vascular endothelial growth factor (VEGF) and also helps regenerate damaged tissue directly. The therapy is currently in Phase I/II clinical trials for Buerger's Disease. In recognition of its potential, VascoStem was granted rare disease status by the U.S. FDA in May 2016, based on early trial data from Korea. It also received orphan drug designation from the European Medicines Agency (EMA) in March 2017.
ATI-1013 - Antidote Therapeutics
ATI-1013 is a fully human monoclonal antibody developed to bind and neutralize nicotine in the bloodstream. Created through an immune-based approach, this antibody is part of a broader program focused on combating nicotine dependence. The development of ATI-1013 has been supported by an $8.5 million Strategic Alliance grant from the National Institute on Drug Abuse (NIDA) at the NIH. The drug has been granted Orphan Drug Designation by the FDA, highlighting its potential to address conditions like Buerger's disease, where nicotine plays a major pathogenic role.
Buerger's Disease Pipeline Therapeutic Assessment

Buerger's Disease Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Buerger's Disease By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Buerger's Disease Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Buerger's Disease Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Buerger's Disease therapies and key Buerger's Disease companies: https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Buerger's Disease Current Treatment Patterns
4. Buerger's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Buerger's Disease Late-Stage Products (Phase-III)
7. Buerger's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Buerger's Disease Discontinued Products
13. Buerger's Disease Product Profiles
14. Buerger's Disease Key Companies
15. Buerger's Disease Key Products
16. Dormant and Discontinued Products
17. Buerger's Disease Unmet Needs
18. Buerger's Disease Future Perspectives
19. Buerger's Disease Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Buerger's Disease pipeline reports offerings: https://www.delveinsight.com/report-store/buergers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.